

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

JCE20 U.S. PTO
09/25/01
07/25/01

IN RE APPLICATION OF: Charles Petrie, et al :

APPLICATION NO.: To be assigned : Examiner: To be assigned

FILING DATE: Concurrently herewith : Group Art Unit: To be assigned

TITLE: Use of Growth Hormone Secretagogues for :
Improvement of Functional Health Status

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: 7/25/01

Martha A. Gammill
Martha A. Gammill
Attorney for Applicant(s)
Reg. No. 31,820

Pfizer Inc.
Patent Department, MS 4159
Eastern Point Road
Groton, Connecticut 06340
(860) 441-5940